Eagle Pharmaceuticals (EGRX): Raising PT After Surprise News But Ahead Of Analyst Day - RBC

November 3, 2016 6:59 AM EDT
Get Alerts EGRX Hot Sheet
Price: $69.31 --0%

Rating Summary:
    4 Buy, 0 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade EGRX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

RBC Capital analyst, Randall Stanicky reiterated his Outperform rating on shares of Eagle Pharmaceuticals (NASDAQ: EGRX) and raised his price target to $93 from $80. The analyst was surprised by the CMS decision to reverse the prior J-code decision and enhances a highly visible cash flow base ahead of several other important updates.

Despite the 19% move yesterday, the analyst believes there is continued momentum ahead with focus now on next week's earnings and analyst day.

For an analyst ratings summary and ratings history on Eagle Pharmaceuticals click here. For more ratings news on Eagle Pharmaceuticals click here.

Shares of Eagle Pharmaceuticals closed at $68.10 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

RBC Capital, Earnings

Add Your Comment